FLT3-ITDs are associated with adverse prognosis due to a high relapse rate, in particular in case of a high mutant to wild-type allele ratio and/or insertion site in the beta1-sheet of the tyrosine kinase domain-1 [22], while the impact of FLT3-TKD mutations remains less clear in AML patients [23]. The gene discussed is FLT3; the disease is acute myeloid leukemia.